Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free AVTE Stock Alerts

Aerovate Therapeutics (AVTE) Competitors

Aerovate Therapeutics logo
$21.23 -1.32 (-5.85%)
As of 08/20/2026
Compare

AVTE vs. RARE, KOD, SLS, COAG, and VRDN

Should you buy Aerovate Therapeutics stock or one of its competitors? Aerovate Therapeutics's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), Kodiak Sciences (KOD), SELLAS Life Sciences Group (SLS), Hemab Therapeutics (COAG), and Viridian Therapeutics (VRDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aerovate Therapeutics compare to Ultragenyx Pharmaceutical?

Aerovate Therapeutics (NASDAQ:AVTE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Ultragenyx Pharmaceutical had 26 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 26 mentions for Ultragenyx Pharmaceutical and 0 mentions for Aerovate Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.14 beat Aerovate Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Ultragenyx Pharmaceutical Positive

Aerovate Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Aerovate Therapeutics' return on equity of -90.19% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Ultragenyx Pharmaceutical -81.79%-1,024.42%-44.40%

Ultragenyx Pharmaceutical has a consensus target price of $58.89, suggesting a potential upside of 127.99%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Ultragenyx Pharmaceutical
1 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.84

Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aerovate Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Ultragenyx Pharmaceutical$673M3.78-$575M-$5.84N/A

Summary

Ultragenyx Pharmaceutical beats Aerovate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Kodiak Sciences?

Aerovate Therapeutics (NASDAQ:AVTE) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Kodiak SciencesN/AN/A-$229.97M-$4.19N/A

Kodiak Sciences has a consensus price target of $48.14, indicating a potential upside of 25.60%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Aerovate Therapeutics' return on equity of -90.19% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Kodiak Sciences N/A -273.23%-85.48%

Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

89.1% of Kodiak Sciences shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Kodiak Sciences had 19 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 19 mentions for Kodiak Sciences and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Kodiak Sciences' score of -0.01 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Kodiak Sciences Neutral

Summary

Kodiak Sciences beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Aerovate Therapeutics (NASDAQ:AVTE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 0 mentions for Aerovate Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.73 beat Aerovate Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Overall Sentiment
SELLAS Life Sciences Group Positive
Aerovate Therapeutics Neutral

SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential downside of 35.32%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, analysts clearly believe SELLAS Life Sciences Group is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

SELLAS Life Sciences Group's return on equity of -35.91% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -35.91% -33.34%
Aerovate Therapeutics N/A -90.19%-77.47%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

SELLAS Life Sciences Group beats Aerovate Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Hemab Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

In the previous week, Hemab Therapeutics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Hemab Therapeutics and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Hemab Therapeutics' score of -0.16 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Hemab Therapeutics Neutral

Hemab Therapeutics has a consensus target price of $51.40, suggesting a potential upside of 4.56%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hemab Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Hemab Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Hemab Therapeutics N/A N/A N/A

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Hemab TherapeuticsN/AN/AN/A-$24.78N/A

Summary

Hemab Therapeutics beats Aerovate Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Aerovate Therapeutics (NASDAQ:AVTE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Viridian Therapeutics presently has a consensus target price of $38.93, suggesting a potential upside of 60.27%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.86
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Aerovate Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Viridian Therapeutics' return on equity of -72.97% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-505.86% -72.97% -42.80%
Aerovate Therapeutics N/A -90.19%-77.47%

Viridian Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Aerovate Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$70.85M38.84-$342.60M-$3.37N/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A

In the previous week, Viridian Therapeutics had 12 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 12 mentions for Viridian Therapeutics and 0 mentions for Aerovate Therapeutics. Viridian Therapeutics' average media sentiment score of 1.04 beat Aerovate Therapeutics' score of 0.00 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Viridian Therapeutics Positive
Aerovate Therapeutics Neutral

Summary

Viridian Therapeutics beats Aerovate Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTE vs. The Competition

Export
MetricAerovate TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$615.35M$3.96B$7.27B$12.76B
Dividend YieldN/A3.64%2.54%11.09%
P/E Ratio-7.1011.52270.6824.19
Price / SalesN/A1,405.85639.49110.97
Price / CashN/A103.2976.8953.23
Price / Book5.3617.9013.436.37
Net Income-$75.52M-$12.50M$3.46B$347.74M
7 Day Performance-10.84%3.22%2.24%0.08%
1 Month Performance7.93%6.53%5.14%2.13%
1 Year Performance188.45%59.76%27.85%20.64%

Aerovate Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTE
Aerovate Therapeutics
N/A$21.23
-5.9%		N/A+206.4%$615.35MN/AN/A20
RARE
Ultragenyx Pharmaceutical
3.4445 of 5 stars		$25.49
-2.4%		$57.82
+126.8%		-13.8%$2.61B$673MN/A1,371
KOD
Kodiak Sciences
2.5424 of 5 stars		$40.65
-0.8%		$48.14
+18.4%		+319.4%$2.59BN/AN/A90
SLS
SELLAS Life Sciences Group
0.9376 of 5 stars		$13.10
+0.8%		$10.00
-23.7%		+624.3%$2.58BN/AN/A10
COAG
Hemab Therapeutics
1.9689 of 5 stars		$52.44
-2.1%		$51.40
-2.0%		N/A$2.57BN/AN/A72

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 8/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel